Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several clinical-mechanism/effect and safety points align directionally with the provided label (e.g., TG-lowering indication, bleeding/antithrombotics monitoring, fish-allergy allergic reaction discussion). However, multiple claims are not supported or are misstated relative to the label excerpt (notably black box warning, Rx-only/prescription requirement, kidney/liver contraindication, characterizing bleeding/allergic reactions as 'rare', and generic/patent/cost/availability statements).
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) contains omega-3 fatty acid ethyl esters of EPA (fish-derived).
Warnings and Precautions 5.2
Vascepa is indicated to reduce triglycerides (TG) in adults with severe hypertriglyceridemia and as adjunct to maximally tolerated statin therapy to reduce risk of major cardiovascular events in adults with elevated TG and established cardiovascular disease or diabetes plus risk factors.
Indications and Usage 1
Vascepa is associated with increased risk of bleeding, with greater incidence in patients receiving concomitant antithrombotic medications (e.g., aspirin, clopidogrel, warfarin).
Warnings and Precautions 5.3
Monitor patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents for bleeding.
Drug Interactions 7.1
Mechanistic language includes reduced hepatic VLDL-TG synthesis and/or secretion and enhanced TG clearance from circulating VLDL particles.
Clinical Pharmacology 12.1
Safety/effectiveness in pediatric patients have not been established.
Pediatric Use 8.4
Unsupported Statements
The patent for Vascepa was set to expire in 2028.
No patent expiration information is present in the provided label sections.
In 2020, the US FDA approved a generic version of Vascepa.
No generic approval timing information is present in the provided label sections.
A generic version of Vascepa is expected to be available in the market.
No future generic availability information is present in the provided label sections.
Vascepa is a prescription-only medication.
No prescription-only/Rx-only status statement is present in the provided label sections.
Vascepa can only be obtained with a valid prescription from a licensed healthcare professional.
No prescription requirement statement is present in the provided label sections.
The use of Vascepa in patients with severe kidney or liver disease is contraindicated.
Provided contraindications only state hypersensitivity to VASCEPA/components; no kidney/liver contraindication is present in the provided contraindications section.
Patients with a history of bleeding disorders should use Vascepa with caution.
The provided label text discusses bleeding risk and monitoring especially with concomitant antithrombotics, but does not specifically address a 'history of bleeding disorders' caution phrasing.
Vascepa may interact with diabetes medications.
No diabetes medication interaction information is present in the provided label sections.
Vascepa may interact with certain antidepressants.
No antidepressant interaction information is present in the provided label sections.
Common side effects of Vascepa include nausea, vomiting, and diarrhea.
The provided common adverse reactions list does not include nausea, vomiting, or diarrhea (instead it lists musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation).
The US FDA has issued a black box warning for Vascepa.
No boxed warning is present in the provided label sections.
The black box warning indicates that Vascepa may increase the risk of bleeding in patients taking anticoagulant medications.
Because no black box warning is present in the provided label sections, this boxed-warning interpretation is not supported.
Vascepa is relatively expensive.
No cost/pricing information is present in the provided label sections.
Availability of generic versions of Vascepa may reduce its cost and make it more accessible to patients.
No generic/cost/accessibility statements are present in the provided label sections.
Contradictions
Low
AI Statement
The US FDA has issued a black box warning for Vascepa.
Label Reference
Boxed warning not shown in provided label sections; warnings are presented under Warnings and Precautions (e.g., Bleeding 5.3) rather than as a black-box statement in the provided excerpt.
Important Omissions
Correct boxed-warning status/context (i.e., whether any boxed warning exists) was not provided in the label evidence used; similarly, detailed administration/dosing guidance is absent from the provided label sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant elements were partially accurate (bleeding risk with antithrombotics; monitoring). However, multiple safety-critical items were unsupported or misstated (e.g., black box warning presence/wording, and broad monitoring framing 'for all patients' not directly supported by provided label text).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Numerous claims are unsupported by the provided FDA label excerpts, including black-box warning, Rx-only/prescription requirement, kidney/liver contraindication, generic/patent/cost/accessibility, and specific interaction and AE characterizations ('rare', 'nausea/vomiting/diarrhea').
Suggested Improvement
Limit claims strictly to the provided label text: use Indications and Usage 1 for approved indications, Contraindications 4 for what is actually contraindicated (hypersensitivity only in provided excerpt), Warnings/Precautions 5.2–5.3 for allergy and bleeding, Drug Interactions 7.1 for monitoring with anticoagulants/antiplatelets, and Adverse Reactions 6.1 for the listed common adverse reactions.